Researchers at Brown University have demonstrated that targeted electrical stimulation of the spinal cord can restore both voluntary movement and sensory feedback in people with chronic, motor-complete spinal cord injuries. The first-in-human clinical trial, conducted with three participants, used implanted electrode arrays placed above and below the injury site to simultaneously activate leg muscles and deliver sensation, a dual achievement that prior approaches had not managed. The results, published in Nature Biomedical Engineering, represent a significant step toward restoring the kind of coordinated function needed for walking.
How Perilesional Stimulation Works
Spinal cord injury causes severe loss of motor, sensory, and autonomic functions by severing the neural pathways that carry signals between the brain and the body. Previous efforts to use epidural electrical stimulation focused on delivering current below the injury to activate muscles, but that approach came with a trade-off. Research in animal models showed that epidural stimulation can interfere with proprioceptive information, the body’s sense of where its limbs are in space. Without proprioception, even electrically activated muscles cannot produce the coordinated gait patterns needed for functional walking.
The new trial took a different approach by placing electrode arrays on both sides of the spinal cord lesion. Stimulation delivered below the injury site activated lower-extremity muscles, while stimulation above the injury provided somatosensory input to the brain. This perilesional strategy essentially rebuilt a two-way communication channel: motor commands flowing down and sensory signals flowing up. All three participants in the trial had chronic injuries classified as motor-complete, meaning they had no voluntary movement below the level of damage before the study began.
By tuning the timing, intensity, and spatial pattern of stimulation, the researchers were able to evoke leg movements that participants could modulate intentionally, suggesting that residual descending pathways were being recruited rather than bypassed. At the same time, stimulation above the lesion generated sensations that participants described as originating from their legs and feet, indicating that ascending sensory pathways could still deliver useful information to the cortex when appropriately engaged.
Building on a Decade of Case Evidence
The trial did not emerge from a vacuum. Case reports in the spinal cord literature had previously shown that epidural stimulation could rapidly enable volitional movement and affect autonomic functions in people with chronic, neurologically complete spinal cord injuries under specific stimulation settings. Those findings established that dormant neural pathways below a spinal lesion could be reactivated, but they left open the question of whether sensation could be simultaneously restored without degrading motor control.
A separate proof-of-concept study combined epidural stimulation with robotic-assisted training, demonstrating immediate muscle activation and pointing toward a future where stimulation devices work alongside powered exoskeletons and other assistive platforms. The perilesional trial advances this trajectory by showing that sensory feedback, not just motor output, can be electrically generated through implanted hardware and integrated into task-specific rehabilitation.
Importantly, the Brown team framed their work as a feasibility study rather than a definitive efficacy trial. With only three participants, the goal was to test whether a dual-array configuration could be implanted safely and whether it could reliably produce both movement and sensation under controlled conditions. The positive results set the stage for larger studies that will need to address variability across injury levels, chronicity, and individual neuroanatomy.
Open Data and Reproducibility
One aspect of the new study that sets it apart from many clinical trials is its commitment to data transparency. The research team deposited participant-level and experiment-level data, including outcome measures and analysis inputs beyond what appears in the published figures, in an open repository dedicated to spinal cord injury research. This means other investigators can directly inspect individual results rather than relying solely on summary statistics.
For a trial with only three participants, that level of openness is especially valuable because it allows independent verification of whether the reported motor activation and sensory restoration held consistently across all subjects or varied in ways the paper’s aggregated results might obscure. It also enables secondary analyses, such as exploring how subtle differences in stimulation parameters correlate with changes in muscle activation patterns or perceived sensation.
More broadly, the data-sharing model aligns with growing expectations that early-stage neurotechnology trials make their methods and datasets available to accelerate replication. Spinal cord injury research has historically been hampered by small sample sizes and heterogeneous protocols; common data resources can help standardize outcome measures and reduce duplication of effort as new teams attempt to refine or extend perilesional strategies.
Noninvasive Alternatives Gain Traction
While the perilesional approach requires surgical implantation of electrode arrays, a parallel track of research is testing whether similar benefits can be achieved without surgery. The Up-LIFT trial, a large multicenter study registered as NCT04697472, used noninvasive transcutaneous spinal cord stimulation paired with structured rehabilitation to improve upper-extremity function in people with chronic cervical incomplete spinal cord injury. Results published in Nature Medicine reported responder rates based on the proportion of participants meeting minimally important differences in hand and arm function.
The distinction between invasive and noninvasive approaches matters for practical reasons. Implanted systems like the one used in the perilesional trial can deliver more precise stimulation to targeted spinal segments, but they carry surgical risks and higher costs. Transcutaneous devices sit on the skin surface and can be applied in outpatient rehabilitation settings without an operating room, making them more accessible to patients who may not be candidates for surgery or who live far from specialized centers.
The U.S. Food and Drug Administration recently classified one such device, the ARC-EX System, through its De Novo pathway under entry DEN240014, defining it as a transcutaneous electrical spine stimulator intended to improve skeletal muscle strength and sensation. That regulatory clearance created a new device category, which means future transcutaneous stimulators can follow a streamlined approval process if they demonstrate comparable safety and performance. In contrast, implanted perilesional systems remain in an earlier stage of development, with regulatory pathways still to be defined.
The Gap Between Proof and Practice
Most coverage of spinal stimulation research emphasizes the promise of restored movement, but the harder question is how quickly these techniques can reach the people who need them. Over half of patients with thoracic spinal cord injury have damage at the T10 through T12 vertebral levels and the conus medullaris, according to research published in a recent analysis. That concentration of injury types suggests a large potential patient population for lower-extremity stimulation, but the perilesional trial’s sample of three people is far too small to establish safety and efficacy at a scale regulators or insurers would accept for broad clinical use.
Long-term data also remain absent. The published results do not include follow-up beyond the initial study period, and no cost-effectiveness analyses have been released for either the implanted or transcutaneous approaches. Without information on durability of benefit, device maintenance, and rehabilitation intensity, it is difficult for health systems to plan reimbursement models or for patients to weigh the trade-offs between surgery and external devices.
Access is another concern. Implant-based perilesional stimulation requires neurosurgical expertise, intraoperative neurophysiology, and specialized post-operative rehabilitation, all of which are concentrated in a small number of academic centers. Even if future trials confirm efficacy, scaling such a complex intervention will depend on training networks, standardized protocols, and sustainable funding. Noninvasive systems may be easier to deploy widely, but they still demand therapists trained in parameter optimization and outcome tracking.
Ethical questions run alongside these logistical challenges. Participants in early-stage trials often receive intensive, personalized care that is difficult to replicate in routine practice. As devices move toward commercialization, developers and clinicians will need to ensure that expectations are calibrated, that benefits are communicated in terms of realistic functional gains rather than cure narratives, and that trial populations reflect the diversity of people living with spinal cord injury.
For now, the Brown University study offers a proof-of-principle that motor and sensory pathways around a spinal lesion can be co-activated using carefully placed electrodes. Combined with open data practices and parallel advances in noninvasive stimulation, it signals a shift from isolated case reports toward a more systematic exploration of how electrical interfaces might help rebuild two-way communication between the brain and the body. Turning that promise into everyday clinical options will require larger trials, long-term follow-up, and deliberate attention to equity and access, but the technical foundation is firmer than it has ever been.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
